Cell-Based Assays November 20, 2011

SMi is proud to present its 4th annual conference on...

Cell-Based Assays
Monday 21st and Tuesday 22nd November 2011, Marriot Hotel, Regents Park, London

http://www.smi-online.co.uk/cell-based33.asp

Overview:

Over the years, SMi has built a reputation as the leading producer of events relating to Cell-Based Assays in Europe. Now in its 4th year, the event has continued to evolve in response to the demands of our delegates and the pharmaceutical industry marketplace. The event will consist of a two day conference and two post-conference workshops, with a focus on a range of topics relating to the challenges facing those involved in using and developing cell-based assays and their importance to the strategic future of R&D in pharma.

Cell-Based Assays is the place for senior scientists from assay development, pharmacology, screening and related fields to meet and discuss progress in the area and exchange ideas moving forward. A dual focus on both strategic and regulatory concerns, alongside more specific scientific and technical analysis, supported with extensive case studies, ensures a truly comprehensive treatment of the most important issues.

Hear from our list of expert speakers who already include:

• Simon T. Barry, Oncology, AstraZeneca
• Firas Bassissi, Senior Scientist/Lab Manager, Preclinical Candidate Selection Unit, Abbott
• Nathan Bays, Research Fellow and Team Lead, High Throughput Flow Cytometry and Cell Biology, Merck & Co
• Davide Danovi, Research Associate, Cancer Unit, University College London
• Laura DeForge, Senior Scientist, Assay & Automation Technology, Genentech
• Alexandra Fuchs, COO, CYTOO Cell Architects
• Cedric Gaggioli, Research Fellow, INSERM
• Anker Jon Hansen, Principal Scientist, Novo Nordisk
• Daniel Kassel, Vice President, Takeda SD
• Stefan Kostense, Director, Clinical Assays, Crucell
• Steven Ludbrook, Cellular Section Head, GSK
• Katharina Maniura, Co-Head, Laboratory for Materials-Biology Interactions, EMPA
• Christian N. Parker, High Throughput Biology, NIBR, Novartis
• Corrine Ploix, Head of Assay Development and Qualification Immunosafety, Centre for Medical Genomics, Roche
• Stefan Przyborski, Director & CSO, Reinnervate and Professor of Cell Technology, University of Durham
• Peter Simpson, Associate Director, Assay Sciences Group, AstraZeneca
• Andrew Southan, Head, Ion Channel Pharmacology, Biofocus
• Glyn Stacey, Director of the UK Stem Cell Bank, NIBSC/HPA
• Pamela Tranter, Group Head, Automated Electrophysiology, Novartis
• Daniel Zicha, Head of Light Microscopy, Cancer Research UK

Why you should attend:
• Learn what new technologies and techniques are making the greatest impact in the area
• Navigate developments in 3D assaying technologies
• Explore the use of stem cells in discovery and development
• Discuss the future of this area and its importance to the sustainability of R&D in pharma
• Benefit from case studies from the world’s leading pharmaceutical companies
• Network with key industry associates and solution providers to share valuable experiences

Sponsorship and Exhibition Opportunities are available

To find out more, contact Alia Malick - Head of Pharmaceuticals

On tel: +44 (0)20 7827 6168 or email: [email protected]

Delegate Information

Visit: http://www.smi-online.co.uk/cell-based33.asp

Contact Zain Philbey +44 (0) 20 7827 6722 / [email protected]

Official Website: http://www.smi-online.co.uk/cell-based33.asp